Role of gut microbiota in liver diseases

Hepatology Research

Volumn 43, Issue 2, 2013, Pages 139-146

  Miyake, Yasuhiro ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Gut microbiota; Inflammasome; Innate immunity; Probiotic; Tolerance; Toll like receptor

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN 9; ENDOTOXIN; FRUCTOSE OLIGOSACCHARIDE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MITOCHONDRION ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ESCHERICHIA COLI; FATTY ACID METABOLISM; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; KUPFFER CELL; LACTOBACILLUS; LIPID DIET; LIVER; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; ULCERATIVE COLITIS;

EID: 84873966954     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01088.x     Document Type: Review

References (87)

1. Sherlock S, Dooley J. Diseases of the Liver and Biliary System, 10th edn. Oxford, MA: Blackwell Science Ltd, 1997.
2. Breous E, Somanathan S, Vandenberghe LH, Wilson JM. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 2009; 50: 612-621.
3. Park O, Jeong WI, Wang L etal. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009; 49: 1683-1694.
4. Dangi A, Sumpter TL, Kimura S etal. Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance. J Immunol 2012; 188: 3667-3677.
5. Visvanathan K, Skinner NA, Thompson AJ etal. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45: 102-110.
6. Takii Y, Nakamura M, Ito M etal. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005; 85: 908-920.
7. Wang AP, Migita K, Ito M etal. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun 2005; 25: 85-91.
8. Yokoyama T, Komori A, Nakamura M etal. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int 2006; 26: 467-476.
9. Wang B, Trippler M, Pei R etal. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. J Hepatol 2009; 51: 1037-1045.
10. Hösel M, Broxtermann M, Janicki H etal. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 2012; 55: 287-297.
11. Dobrovolskaia MA, Medvedev AE, Thomas KE etal. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components. J Immunol 2003; 170: 508-519.
12. Singh R, Bullard J, Kalra M etal. Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. Clin Immunol 2011; 138: 41-49.
13. Harada K, Isse K, Sato Y, Ozaki S, Nakanuma Y. Endotoxin tolerance in human intrahepatic biliary epithelial cells is induced by upregulation of IRAK-M. Liver Int 2006; 26: 935-942.
14. Zhao J, Zhao S, Zhou G etal. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis. Scand J Gastroenterol 2011; 46: 485-494.
15. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
16. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 370-379.
17. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
18. Thuy S, Ladurner R, Volynets V etal. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452-1455.
19. Li L, Chen L, Hu L etal. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011; 54: 1620-1630.
20. Miele L, Valenza V, La Torre G etal. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
21. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-579.
22. Miura K, Kodama Y, Inokuchi S etal. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010; 139: 323-334.
23. Leroux A, Ferrere G, Godie V etal. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012; 57: 141-149.
24. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49: 821-830.
25. Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005; 42: 880-885.
26. Esposito E, Iacono A, Bianco G etal. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009; 139: 905-911.
27. Li Z, Yang S, Lin H etal. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350.
28. Malaguarnera M, Vacante M, Antic T etal. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-553.
29. Syn WK, Oo YH, Pereira TA etal. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010; 51: 1998-2007.
30. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011; 54: 133-144.
31. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012; 481: 278-286.
32. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006; 26: 22-30.
33. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 2002; 51: 120-127.
34. Karrar A, Broomé U, Södergren T etal. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007; 132: 1504-1514.
35. Muller T, Beutler C, Picó AH etal. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int 2011; 31: 1574-1588.
36. O'Toole A, Alakkari A, Keegan D, Doherty G, Mulcahy H, O'Donoghue D. Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 439-441.
37. Ye BD, Yang SK, Boo SJ etal. Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea. Inflamm Bowel Dis 2011; 17: 1901-1906.
38. Hashimoto E, Ideta M, Taniai M etal. Prevalence of primary sclerosing cholangitis and other liver diseases in Japanese patients with chronic ulcerative colitis. J Gastroenterol Hepatol 1993; 8: 146-149.
39. Bergquist A, Montgomery SM, Bahmanyar S etal. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6: 939-943.
40. Bambha K, Kim WR, Talwalkar J etal. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-1369.
41. Sano H, Nakazawa T, Ando T etal. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2011; 18: 154-161.
42. Joo M, Abreu-e-Lima P, Farraye F etal. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009; 33: 854-862.
43. Pastor Rojo O, López San Román A, Albéniz Arbizu E etal. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 269-277.
44. Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 2009; 51: 149-155.
45. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994; 107: 532-536.
46. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-417.
47. Terjung B, Herzog V, Worman HJ etal. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998; 28: 332-340.
48. Terjung B, Söhne J, Lechtenberg B etal. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010; 59: 808-816.
49. McGovern DP, Gardet A, Törkvist L etal. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 332-337.
50. Janse M, Lamberts LE, Franke L etal. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011; 53: 1977-1985.
51. Gross O, Gewies A, Finger K etal. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006; 442: 651-656.
52. Brown GD, Taylor PR, Reid DM etal. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 2002; 196: 407-412.
53. Gringhuis SI, Kaptein TM, Wevers BA etal. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat Immunol 2012; 13: 246-254.
54. Tsoni SV, Brown G. D. beta-Glucans and dectin-1. Ann N Y Acad Sci 2008; 1143: 45-60.
55. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 2011; 377: 1600-1609.
56. Mao TK, Lian ZX, Selmi C etal. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 2005; 42: 802-808.
57. Honda Y, Yamagiwa S, Matsuda Y, Takamura M, Ichida T, Aoyagi Y. Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis. J Hepatol 2007; 47: 404-411.
58. Kikuchi K, Lian ZX, Yang GX etal. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology 2005; 128: 304-312.
59. Shimoda S, Harada K, Niiro H etal. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 2011; 53: 1270-1281.
60. Hopf U, Möller B, Stemerowicz R etal. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 1989; 2: 1419-1422.
61. Bogdanos DP, Baum H, Grasso A etal. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004; 40: 31-39.
62. Bogdanos DP, Baum H, Okamoto M etal. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 2005; 42: 458-465.
63. Selmi C, Balkwill DL, Invernizzi P etal. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003; 38: 1250-1257.
64. Nardone G, Compare D, Liguori E etal. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol 2010; 299: G669-676.
65. Osman N, Adawi D, Ahrné S, Jeppsson B, Molin G. Endotoxin- and d-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Dig Liver Dis 2007; 39: 849-856.
66. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009; 43: 163-172.
67. Kirpich IA, Solovieva NV, Leikhter SN etal. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675-682.
68. Björkholm B, Bok CM, Lundin A, Rafter J, Hibberd ML, Pettersson S. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS ONE 2009; 4: e6958.
69. Chuang HL, Huang YT, Chiu CC etal. Metabolomics characterization of energy metabolism reveals glycogen accumulation in gut-microbiota-lacking mice. J Nutr Biochem 2012; 23: 752-758.
70. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-1449.
71. Xie N, Cui Y, Yin YN etal. Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet. BMC Complement Altern Med 2011; 11: 53.
72. Söderberg C, Marmur J, Eckes K etal. Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis. APMIS 2011; 119: 412-420.
73. Yokohama S, Tokusashi Y, Nakamura K etal. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12: 322-326.
74. Bertola A, Bonnafous S, Anty R etal. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS ONE 2010; 5: e13577.
75. Lan RY, Salunga TL, Tsuneyama K etal. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009; 32: 43-51.
76. Yoneda M, Naka S, Nakano K etal. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol 2012; 12: 16.
77. Koyabu M, Uchida K, Miyoshi H etal. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol 2010; 45: 732-741.
78. Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998; 29: 409-416.
79. Krasinskas AM, Yao Y, Randhawa P, Dore MP, Sepulveda AR. Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 2265-2270.
80. Ponsioen CY, Defoer J, Ten Kate FJ etal. A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved? Eur J Gastroenterol Hepatol 2002; 14: 641-648.
81. Kita H, Naidenko OV, Kronenberg M etal. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002; 123: 1031-1043.
82. Sánchez-Muñoz D, Castellano-Megías VM, Romero-Gómez M. Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis. Dig Liver Dis 2007; 39: 262-266.
83. Nagano T, Yamamoto K, Matsumoto S etal. Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol 1999; 19: 422-427.
84. Zimmermann HW, Seidler S, Gassler N etal. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS ONE 2011; 6: e21381.
85. Berg CP, Kannan TR, Klein R etal. Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis. Liver Int 2009; 29: 797-809.
86. Haruta I, Kikuchi K, Hashimoto E etal. A possible role of histone-like DNA-binding protein of Streptococcus intermedius in the pathogenesis of bile duct damage in primary biliary cirrhosis. Clin Immunol 2008; 127: 245-251.
87. Harada K, Tsuneyama K, Sudo Y, Masuda S, Nakanuma Y. Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis: is Propionibacterium acnes involved in granuloma formation? Hepatology 2001; 33: 530-536.